- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07587762
Predicting the Clinical Advantages of Speaking Valves Through Wearable Devices
Predicting the Clinical Advantages of Speaking Valves Through Wearable Devices:A Prospective Cohort Study
The population included in this study consists of tracheostomy patients admitted to the pulmonary department of Beijing Rehabilitation Hospital, undergoing decannulation rehabilitation treatment. Once patient conditions stabilized, they were all transitioned to the decannulation process established by our department in 2018, which utilizes a speaking valve instead of capping.The initial duration for the patient to wear the speaking valve is 30 minutes.The monitoring period for wearable devices is from 1 hour before the initial use of the speaking valve to 1 hour after its removal.Monitored for a total of 2 hours and 30 minutes.Explore the clinical benefits of the speaking valve by comparing the changes in patients' physiological parameters and clinical index metrics before and after using the speaking valve.
Criteria for the successful use of the speaking valve for 30 minutes:
- Breathing is steady at rest: no apparent dyspnea, chest tightness, or orthopnea, etc.
- Heart rate, blood pressure, and SpO₂ are all stable overall.SpO₂ reduction from baseline < 5%.
- No frequent need for emergency sputum suction or indications of sputum blockage while wearing it.
Visão geral do estudo
Status
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100144
- Beijing Rehabilitation Hospital, Capital Medical University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- 90 years≥Age≥18 years;
- Tracheotomy post-operation>48 hours;
- Weaned off mechanical ventilation;
- Clinically stable condition;
- Tolerable for cuff deflation;
- Able to tolerate wearing a speaking valve continuously for 30 minutes;
- Signed informed consent.
Exclusion Criteria:
- Patients with abnormal skin conditions preventing continuous wearing of monitoring devices;
- Inability to tolerate wearing a speaking valve continuously for 30 minutes;
- Interruption of physiological monitoring data;
- Poor quality of physiological monitoring data;
- Recently underwent neck/upper airway surgery (≤48 hours, to avoid airflow impact on the upper airway);
- Severe consciousness disturbance/delirium (RASS score≤-3 or ≥ +2), extreme anxiety/uncooperativeness;
- Total laryngectomy or laryngotracheal separation;
- Age <18 years or >90 years;
- Malignant tumor with an expected survival time ≤6 months;
- The patient or legal representative is unable to sign the informed consent form.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Successfully wore the speaking valve for the first time for 30 minutes.
Inclusion Criteria:
|
Once patient conditions stabilized, they were all transitioned to the decannulation process established by our department in 2018, which utilizes a speaking valve instead of capping.The initial duration for the patient to wear the speaking valve is 30 minutes.If the patient can tolerate wearing the speaking valve for 30 minutes, they fulfill the inclusion criteria.The monitoring period for wearable devices is from 1 hour before the initial use of the speaking valve to 1 hour after its removal.Monitored for a total of 2 hours and 30 minutes. Physiological parameters recorded prior to wearing the speaking valve served as the baseline.Compare the physiological parameters while wearing the speaking valve and after its removal to investigate the clinical benefits that the speaking valve can provide.To promote the application of speaking valves in future clinical work more effectively |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
degree of change in oxygen saturation(%)
Prazo: Using wearable biosensors, high-resolution physiological data were continuously collected during three phases: baseline (30 minutes), speaking valve placement period (30 minutes), and recovery period (30 minutes after speaking valve removal).
|
Previous studies have been concerned that speaking valve placement increases upper airway resistance, thereby inducing dyspnea and hypoxemia in patients.
Therefore, we used continuous wearable physiological monitoring devices to observe changes in oxygen saturation before, during, and after the training.
|
Using wearable biosensors, high-resolution physiological data were continuously collected during three phases: baseline (30 minutes), speaking valve placement period (30 minutes), and recovery period (30 minutes after speaking valve removal).
|
|
Temporal rate of change of asymmetric cardiovascular responses and delayed autonomic recovery(percentage change from baseline)
Prazo: 30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session
|
The rate of change (percentage per minute) in asymmetric cardiovascular responses (e.g., heart rate variability indices) and delayed autonomic recovery will be calculated.
Physiological data (heart rate, HRV metrics) are continuously collected before, during, and after speaking valve placement.
The primary reported value is the slope of change over time, expressed as a percentage relative to baseline, aggregated across all participants using mixed-effects modeling to produce a single mean rate of change
|
30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session
|
|
Rate of respiratory phase variation during training(percentage change in phase duration)
Prazo: 30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session
|
The rate of change in respiratory phase variation (e.g., changes in inspiratory/expiratory time proportion) during speaking valve training.
Respiratory parameters are continuously recorded.
The outcome is the calculated rate of change (percentage per minute) from baseline to the active training period and to the recovery period.
A single aggregated value (mean slope) will be derived from all participants using linear mixed models.
|
30 minutes before speaking valve placement, throughout the entire training session (i.e., during valve wear), and 30 minutes after the training session
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Cadeira de estudo: Hongying Jiang, Beijing Rehabilitation Hospital of Capital Medical University, Beijing, China
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 2026-bjkfyy-SVB
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .